Core Viewpoint - Nanmo Biology (688265.SH) is currently experiencing a decline in stock price, with a closing price of 47.49 yuan and a drop of 4.06%, indicating a state of being below its initial public offering price [1] Group 1: Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached a peak price of 82.00 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan, as the company initially aimed to raise 400 million yuan for various projects [1] - The total issuance costs amounted to 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [1] Group 3: Planned Use of Funds - The funds raised are intended for several projects, including the establishment of a biological research base, construction of a genetically modified model resource library, development of humanized antibody mouse models, and a drug efficacy platform based on genetically modified animal models, as well as to supplement working capital [1]

人民财讯9月22日电，企查查APP显示，近日，贵州茅台（600519）生物科技研发有限责任公司成立， 法定代表人为杨帆，注册资本10亿人民币，经营范围含生物化工产品技术研发、发酵过程优化技术研 发、工业酶制剂研发、细胞技术研发和应用、生物农药技术研发等。企查查股权穿透显示，该公司由中 国贵州茅台酒厂(集团)有限责任公司、贵州茅台共同持股。 ...

Core Insights - Guizhou Moutai Biotech Research Co., Ltd. was established on September 19 with a registered capital of 1 billion RMB, focusing on various biotechnological research areas [1] Company Overview - The company is co-owned by China Guizhou Moutai Distillery (Group) Co., Ltd. and Guizhou Moutai Distillery Co., Ltd. [1] - The legal representative of the new company is Yang Fan [1] Industry Position - Moutai ranks third in the "2025 Kantar BrandZ Most Valuable Chinese Brands" list with a brand value of 80.023 billion USD, approximately 569.421 billion RMB, following Tencent and Alibaba [1]

南模生物上市首日盘中最高价报82.00元，为该股上市以来最高价。 南模生物首次公开发行股票募集资金总额为16.49亿元，扣除发行费用后募集资金净额为14.68亿元。南 模生物最终募集资金净额比原计划多10.68亿元。南模生物于2021年12月23日披露的招股说明书显示， 该公司拟募集资金4.00亿元，分别用于上海砥石生物科技有限公司生物研发基地项目(南方模式生物)、 基因修饰模型资源库建设项目、人源化抗体小鼠模型研发项目、基于基因修饰动物模型的药效平台建设 项目、补充流动资金项目。 南模生物首次公开发行股票的发行费用总额为1.81亿元，其中，保荐及承销费用1.58亿元。 中国经济网北京9月10日讯南模生物(688265.SH)今日股价下跌，截至收盘，该股报54.64元，跌幅 4.09%。该股目前处于破发状态。 南模生物于2021年12月28日在上交所科创板上市，发行股票数量为1949.09万股，发行价格为84.62元/ 股，保荐人(主承销商)为海通证券股份有限公司(现更名为国泰海通证券股份有限公司)，保荐代表人为 张子慧、陈亚聪。 ...

Fundraising Overview - The company raised a total of RMB 1,649,319,958.00 by issuing 19,490,900 shares at a price of RMB 84.62 per share, with a net amount of RMB 1,467,876,199.92 after deducting issuance costs [1][2] - As of June 30, 2025, the total net amount of raised funds was RMB 146,787.62 million, with RMB 146,308.22 million invested in projects and RMB 1,794.24 million in net interest income [1][2] Fund Management - The company established a management method for the raised funds, adhering to regulations to ensure proper management and usage, including a dedicated account storage system [1][2] - Six dedicated accounts for the raised funds have been closed as of June 30, 2025, indicating a complete utilization of the funds [1][2] Fund Utilization - The company did not have any idle funds or temporary use of idle funds for working capital during the reporting period [1][2] - All investment projects funded by the raised capital, including the "Gene Modification Model Resource Library" and "Humanized Antibody Mouse Model Development," have been completed [4][5] Cash Management - The company approved the use of up to RMB 80 million of excess and idle funds for cash management, allowing for cyclical use within a 12-month period starting from February 1, 2024 [1][2] Compliance and Reporting - The company confirmed that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no significant violations in fund usage [1][2]